Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand

Douglas S. Walsh; Sornchai Looareesuwan; Polrat Wilairatana; D. Gray Heppner; Douglas B. Tang; Thomas G. Brewer; Watcharee Chokejindachai; Parnpen Viriyavejakul; Dennis E. Kyle; Wilbur K. Milhous; Brian G. Schuster; John Horton; David J. Braitman; Ralf P. Brueckner

doi:10.1086/315034

Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand

Douglas S. Walsh
, Sornchai Looareesuwan
, Polrat Wilairatana
, D. Gray Heppner
, Douglas B. Tang
, Thomas G. Brewer
, Watcharee Chokejindachai
, Parnpen Viriyavejakul
, Dennis E. Kyle
, Wilbur K. Milhous
, Brian G. Schuster
, John Horton
, David J. Braitman
, Ralf P. Brueckner

Hospital for Tropical Diseases, Bangkok
Walter Reed Army Institute of Research
GlaxoSmithKline Vaccines
U.S. Army Medical Materiel Development Activity

Research output: Contribution to journal › Article › peer-review

102 Citations (Scopus)

Abstract

WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily for 7 days; group B (n = 11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n = 9), 1 dose of 500 mg. A fourth group (D; n = 9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n = 23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.

Original language	English
Pages (from-to)	1282-1287
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	180
Issue number	4
DOIs	https://doi.org/10.1086/315034
Publication status	Published - 1999
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1086/315034

Cite this

Walsh, D. S., Looareesuwan, S., Wilairatana, P., Gray Heppner, D., Tang, D. B., Brewer, T. G., Chokejindachai, W., Viriyavejakul, P., Kyle, D. E., Milhous, W. K., Schuster, B. G., Horton, J., Braitman, D. J., & Brueckner, R. P. (1999). Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. Journal of Infectious Diseases, 180(4), 1282-1287. https://doi.org/10.1086/315034

@article{e8bdda8bae844850bf7f757e88978958,

title = "Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand",

abstract = "WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily for 7 days; group B (n = 11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n = 9), 1 dose of 500 mg. A fourth group (D; n = 9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n = 23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.",

author = "Walsh, \{Douglas S.\} and Sornchai Looareesuwan and Polrat Wilairatana and \{Gray Heppner\}, D. and Tang, \{Douglas B.\} and Brewer, \{Thomas G.\} and Watcharee Chokejindachai and Parnpen Viriyavejakul and Kyle, \{Dennis E.\} and Milhous, \{Wilbur K.\} and Schuster, \{Brian G.\} and John Horton and Braitman, \{David J.\} and Brueckner, \{Ralf P.\}",

year = "1999",

doi = "10.1086/315034",

language = "English",

volume = "180",

pages = "1282--1287",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "4",

}

Walsh, DS, Looareesuwan, S, Wilairatana, P, Gray Heppner, D, Tang, DB, Brewer, TG, Chokejindachai, W, Viriyavejakul, P, Kyle, DE, Milhous, WK, Schuster, BG, Horton, J, Braitman, DJ & Brueckner, RP 1999, 'Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand', Journal of Infectious Diseases, vol. 180, no. 4, pp. 1282-1287. https://doi.org/10.1086/315034

TY - JOUR

T1 - Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand

AU - Walsh, Douglas S.

AU - Looareesuwan, Sornchai

AU - Wilairatana, Polrat

AU - Gray Heppner, D.

AU - Tang, Douglas B.

AU - Brewer, Thomas G.

AU - Chokejindachai, Watcharee

AU - Viriyavejakul, Parnpen

AU - Kyle, Dennis E.

AU - Milhous, Wilbur K.

AU - Schuster, Brian G.

AU - Horton, John

AU - Braitman, David J.

AU - Brueckner, Ralf P.

PY - 1999

Y1 - 1999

N2 - WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily for 7 days; group B (n = 11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n = 9), 1 dose of 500 mg. A fourth group (D; n = 9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n = 23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.

AB - WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n = 15) received 300 mg daily for 7 days; group B (n = 11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n = 9), 1 dose of 500 mg. A fourth group (D; n = 9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n = 23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.

UR - https://www.scopus.com/pages/publications/0033383602

U2 - 10.1086/315034

DO - 10.1086/315034

M3 - Article

C2 - 10479159

AN - SCOPUS:0033383602

SN - 0022-1899

VL - 180

SP - 1282

EP - 1287

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 4

ER -

Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this